Araim Pharmaceuticals’ ARA 290 significantly improves islet cell function following islet cell transplantation in a model of Type 1 diabetes Araim Pharmaceuticals’ ARA 290 significantly improves islet cell function following islet cell transplantation in a model of Type 1 diabetes admin-araim-2015 2015-12-23T14:52:46+00:00 December 23rd, 2015|Press Release|
December 17, 2014 Molecular Medicine Issues 20th Anniversary Edition. Journal Focuses on the legacy and impact of Anthony Cerami’s groundbreaking work on diabetes Molecular Medicine Issues 20th Anniversary Edition. Journal Focuses on the legacy and impact of Anthony Cerami’s groundbreaking work on diabetes admin-araim-2015 2015-12-23T14:44:12+00:00 December 17th, 2014|Press Release|
New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes admin-araim-2015 2015-12-23T14:48:29+00:00 December 15th, 2014|Uncategorized|
Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis (Dutch Version) Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis (Dutch Version) admin-araim-2015 2015-12-23T14:49:17+00:00 December 1st, 2014|Press Release|
Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy admin-araim-2015 2015-12-23T14:50:14+00:00 October 28th, 2014|Press Release|
Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission admin-araim-2015 2015-12-23T14:51:02+00:00 October 10th, 2013|Press Release|
